iRhythm Technologies (IRTC) Faces Growing Losses as Revenue Growth Outpaces US Market Expectations

iRhythm Technologies (IRTC) is expected to deliver revenue growth of 14.3% per year, outpacing the broader US market’s 10.3% growth rate. While the company remains unprofitable at present, earnings are projected to climb rapidly at a 74.62% annual pace with profitability on the horizon within the next three years. Investors are weighing these strong growth prospects against the fact that losses have actually increased by 12.5% per year over the past five years, setting up high expectations for a turnaround.

See our full analysis for iRhythm Technologies.

Next, we’ll see how the latest figures measure up to the current narrative around iRhythm. This will highlight where consensus thinking is supported and where the numbers might challenge the story.

See what the community is saying about iRhythm Technologies

Premium Price-to-Sales Ratio Signals High Expectations

• iRhythm trades at a price-to-sales ratio of 9.2x, which is notably higher than peers (5.8x) and the broader US Medical Equipment industry (3.1x). This implies that investors expect outsized growth and strong future profitability, even as the company remains in the red.
• According to the analysts' consensus view, this premium valuation is justified by expanding adoption in primary care and international markets, as well as continued investment in advanced features and AI analytics that bolster both product differentiation and efficiency.
  • The consensus sees ongoing volume growth from new partnerships and market expansion fueling recurring revenue streams and improved margins.
  • While bulls may find the high multiple warranted, it raises the stakes for delivering on these growth expectations, especially given that robust competition and fragile profitability could make the target margins harder to achieve.
• For investors weighing the consensus perspective, fresh results make the case to check if the value proposition stacks up. See the full consensus narrative for a data-driven read on both sides.📊 Read the full iRhythm Technologies Consensus Narrative.

Profit Margins Seen Turning Positive by 2027

• Analysts expect iRhythm’s margins to shift from -14.1% today to 4.7% by 2027, reflecting not just revenue growth but also significant operational leverage as advanced product features and recurring software usage drive higher gross margins over time.
• The consensus narrative highlights how investments in next-gen patches, AI-powered analytics, and workflow efficiency are likely to improve diagnostic yield, with multiple value-based contracts and partnerships providing a base for scaling margins.
  • These recurring usage patterns are critical, supporting both the case for increasing net margins and the sustainability of long-term profitability, even as current losses persist.
  • The pathway to margin expansion is not without friction, as execution and customer concentration risks remain points to monitor against these optimistic scenarios.

Current Share Price Narrowly Tracks Analyst Target

• At a share price of $187.30, iRhythm sits just below the analyst target of 211.67, which means the market currently assigns a 13% potential upside based on consensus future earnings, projected margin expansion, and revenue growth.
• Consensus narrative notes that the relatively small gap between the share price and analyst target suggests the company is seen as fairly valued, and that investors would need to believe in a rapid shift to $49.7 million in annual earnings (and a steep 156.2x PE) by 2028 to fully back the target.
  • This expectation relies on assumptions of sharper margin recovery and successful scaling, both of which will hinge on maintaining innovation and competitive differentiation in a fast-changing medtech environment.
  • The stock’s valuation leaves little room for error, so progress on regulatory hurdles, product launches, and international expansion will likely drive near-term sentiment.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for iRhythm Technologies on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Have your own take on the data? Share your perspective and contribute your narrative in just a few minutes. Do it your way

A great starting point for your iRhythm Technologies research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

Explore Alternatives

Despite strong revenue growth forecasts, iRhythm remains unprofitable and faces pressure from high valuation multiples. Profitability and execution risks are still looming.

If you’re seeking more reliable value and downside protection, check out these 832 undervalued stocks based on cash flows that offer attractive opportunities without the elevated risk and lofty expectations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com